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A major goal of molecular biology is to elucidate the mechanisms underlying cancer development and 
progression in order to achieve early detection, better diagnosis and staging and novel preventive and 
therapeutic strategies. We feel that an understanding of Runt-related transcription factor 3 
(RUNX3)-regulated biological pathways will directly impact our knowledge of these areas of human 
carcinogenesis. The RUNX3 transcription factor is a downstream effector of the transforming growth 
factor-beta (TGF-β) signaling pathway, and has a critical role in the regulation of cell proliferation and cell 
death by apoptosis, and in angiogenesis, cell adhesion and invasion. We previously identified RUNX3 as a 
major gastric tumor suppressor by establishing a causal relationship between loss of function and gastric 
carcinogenesis. More recently, we showed that RUNX3 functions as a bona fide initiator of colonic 
carcinogenesis by linking the Wnt oncogenic and TGF-β tumor suppressive pathways. Apart from gastric 
and colorectal cancers, a multitude of epithelial cancers exhibit inactivation of RUNX3, thereby making it a 
putative tumor suppressor in human neoplasia. This review highlights our current understanding of the 
molecular mechanisms of RUNX3 inactivation in the context of cancer development and progression. 
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       Transcription factors encoded by the RUNX (Runt-related transcription factor) family of genes 
(RUNX1, RUNX2 and RUNX3) [1] bind DNA by partnering with the cofactor, CBFβ/PEBP2 
(core-binding factor beta subunit/polyomavirus enhancer-binding protein 2 beta subunit). The resultant 
complex activates and represses the transcription of principle regulators of growth, survival and 
differentiation pathways. CBFβ/PEBP2, a non-DNA binding partner that is shared by the RUNX proteins, 
confers high-affinity DNA binding and stability to the complex. RUNX regulates the expression of cellular 
genes by binding to promoters/enhancers of target genes related to cell-fate decisions, which become 
deranged in neoplastic cells. Runx1, which has been implicated in hematopoiesis [2,3] is also a frequent 
target of chromosomal translocations in distinct leukemia subtypes [4]. Runx2, which is essential for 
osteogenesis [5,6], is altered in cleido cranial dysplasia [7]. Runx3 is necessary for gastric epithelial growth 
[8], neurogenesis of dorsal root ganglia [9,10] and T-cell differentiation [11]. Runx3 knockout mice 
exhibited gastric epithelial hyperplasia, reduced apoptosis and reduced sensitivity to TGF-β1 [8].  About 
45% to 60% of human gastric cancers displayed loss of RUNX3 expression due to hemizygous deletion and 
promoter hypermethylation. A single loss-of-function mutation of RUNX3 (R122C) in the conserved Runt 
domain was noted. These findings were the first demonstration of a causal link between loss of RUNX3 
functions and gastric carcinogenesis [8]. Since then, RUNX3 has emerged as a candidate tumor suppressor 
that is epigenetically inactivated in a wide spectrum of invasive [12-29] and pre-invasive 
[12,15,16,21,30,31,32, 73] epithelial and mesenchymal neoplasms [27]. A recent paradigm shift discovery 
by our group indicated that RUNX3 forms a ternary complex with β-catenin/TCF4 and attenuates Wnt 
signaling activity in initiating the development of colorectal cancer (CRC) [32]. Besides hypermethylation, 
inactivation of RUNX3 also occurs by mislocalization of RUNX3 protein from the nucleus to the 
cytoplasm [13,20,30-32]. On one hand, inactivating mutations, gene deletions, promoter hypermethylation 
and protein mislocalization point to a tumor-suppressor function of RUNX3 in a majority of human 
cancers; on the other hand, transcriptional activation by retroviral insertion clearly indicates its dominant 
oncogenic potential. The latter potential can be seen in Burkitt’s lymphoma cell lines (group III), which 
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have upregulated expression of c-myc and EBNA2, and, in turn, induce increased RUNX3 expression [33]. 
Additionally, RUNX3 is overexpressed in human basal cell carcinomas (BCC) [34], a skin cancer 
associated with deregulated Sonic hedgehog signaling as well as in head and neck squamous cell 
carcinomas [35] which suggests that RUNX3 has a bona fide oncogenic function. It is not clear how 
RUNX3 deregulation occurs via such contrasting mechanisms. In addition, how and where RUNX3 
interacts with pathways that regulate growth control and differentiation are still obscure. Investigations of 
the factors controlling RUNX3 function and its downstream effectors have begun to unravel this biological 
mystery. This review focuses on the existing knowledge of the role of the RUNX3 gene in formation of 
human solid tumors/cancers and includes recent data from our group. We also discuss the 
clinico-pathological, prognostic and therapeutic implications of RUNX3 in different cancer types, and 




2. Overview of RUNX3 signaling in cancer 
      Runx3-/- knock-out mice presented the following features: 1) the gastric epithelium of Runx3-/- mice 
displayed hyperplasia due to increased cellular proliferation and reduced apoptosis; 2) Runx3-/- gastric 
epithelial cells were insensitive to the growth inhibitory effects of TGF-β; and 3) in nude mice, gastric 
epithelial cells from Runx3-/- mice with a p53-/- background were tumorigenic, whereas their cellular 
counterparts from Runx3+/+p53-/- mice were not [8]. These findings indicate features of a novel tumor 
suppressor, RUNX3, that regulate cell proliferation and cell death by apoptosis. Recent additions to these 
classical functions of RUNX3 include interaction with DNA repair proteins [36], inhibition of angiogenesis 
[37], and involvement in cell adhesion and invasion [38].  The 1p36 locus that houses RUNX3 is 
frequently deleted in a variety of cancers, and is therefore proposed to contain crucial tumor suppressor 
genes [39]. The TGF-β pathway is deranged in a majority of these cancers, and RUNX3, being a 
downstream effector of TGF-β [40], might provide an explanation for its broad involvement in human 
tumorigenesis. Table 1 summarizes the role of RUNX3 inactivation in tumors of different organ systems. 
3. RUNX3 inactivation in human invasive and pre-invasive cancers 
3.1. Gastric cancer 
       The tumor suppressive functions of RUNX3 were firstly reported in gastric epithelial cells [8] and 
the molecular basis revealed in gastric cancer precedes the RUNX3 studies on the other human cancers. 
Here, we discuss the mechanisms by which RUNX3 exercises its tumor suppressive activity and its 
interaction with other cancer-signaling molecules in the context of gastric carcinogenesis (Figure 1). 
3.1.1. RUNX3 integration in the Transforming growth factor (TGF)- β signaling pathway  
       Transforming growth factor-β when bound to their respective cognate receptors are activated as 
serine kinases, which then phosphorylate signal transducers called Smads. TGF-β activates Smad2 and 3 
(R-Smads), which associate with a common Smad4 (Co-Smad) and enter the nucleus, where the 
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R-Smad/Co-Smad complexes bind to transcription factors in order to regulate the transcription of target 
genes. RUNX3 interacts with R-Smads as well as p300, a transcriptional co-activator. Smad2/3, Smad4, 
p300 and RUNX3 are collectively required for the tumor suppressor activity of the TGF-β pathway [40]. 
TGF-β causes cell cycle arrest at the mid-and late-G1 phases of the cell cycle by inactivating 
cyclin-dependent kinases (cdks) through the induction of cdk inhibitors. However, the lineage-specific 
transcription factor that cooperates with Smads to induce p21 expression was unknown at that time. Chi et 
al. (2005) [41] showed that RUNX3 inhibits gastric epithelial cell growth by inducing p21 gene expression 
in response to TGF-β1. Exogenous RUNX3 expression increased endogenous p21 expression in response 
to TGF-β1, suggesting the involvement of RUNX3 in the TGF-β pathway. RUNX3 suppression decreased 
TGF-β1-induced endogenous p21 expression. Together, these results indicate that the tumor suppressor 
activity of RUNX3 is partially linked to its ability to induce p21 expression [41]. RUNX3 binds to 
conserved RUNX binding elements (RBE1 and RBE2) in the Bim (the Bcl-2 interacting mediator of cell 
death) promoter, and physically interacts with the Forkhead transcription factor, FoxO3a/FKHRL1, an 
important regulator of apoptosis and the cell cycle, to activate the expression of Bim, a proapoptotic gene 
[42]. The gastric epithelium of Runx3-/- mice had reduced levels of Bim expression, and of apoptosis, which 
was reduced to a similar extent as in Bim-/- mice. Furthermore, comparable expression of TGF-β1 and 
TGF-β receptors was noted in the wild-type and Runx3-/- gastric epithelium, and levels of Bim were 
reduced in the stomachs of TGF-β-/- mice, thereby confirming the role of RUNX3 in Bim upregulation in 
TGF-β-induced apoptosis [43]. GASDERMIN (GSDM), was found to be expressed in the gastric pit 
epithelial cells, but to be suppressed in gastric cancer cell lines [44]. GSDM possesses high apoptotic 
activity, and its expression is regulated by a transcription factor, Lim domain only 1 (LMO1), through a 
sequence to which RUNX3 binds in the GSDM promoter region [45]. Coexpression of GSDM with LMO1, 
RUNX3 and type II TGF-β receptor (TGF-βRII) was detected in gastric pit cells [45]. In addition, TGF-β 
upregulated LMO-1 and GSDM expression in the gastric epithelial cell lines, and induced apoptosis. This 
confirmed that induction of apoptosis is inhibited by the suppression of LMO-1, RUNX3 or GSDM 
expression [45]. 
3.1.2. Apoptosis via the death-receptor mitochondria-mediated pathway 
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       In the MKN-1 gastric cancer cell line, forced RUNX3 expression in the Tet-regulated adenoviral 
vector induced apoptosis by death-receptor molecules. RUNX3 upregulated 17 apoptosis-related genes, 
including Fas-associated death domain, (FADD), TRAF6, Caspase-2, ING1, ING4, Calpain 10 and DNase 
1, and downregulated 135 apoptosis-related genes, including FLICE/caspase-8 inhibitory protein (FLIP), 
PEA15, TXN2, HSPD1, IKK and TIAL1. Further analyses also suggested that promotion of the formation 
of the death-inducing signaling complex and activation of the mitochondria-mediated pathway were 
associated with RUNX3-induced apoptosis. These results suggest that exogenous RUNX3 expression 
suppresses cell proliferation by inducing apoptosis via the death-receptor mitochondria-mediated pathway 
in MKN-1 cells [46]. 
 
3.1.3. RUNX3 inactivation by histone modification mechanisms 
       The expression of RUNX3 was downregulated at the transcriptional level in response to hypoxia 
in human gastric cancer cells. This downregulation was abolished by treatment with the histone 
deacetylase (HDAC) inhibitor, trichostatin A (TSA), and the cytosine methylation inhibitor, 
5-aza-2-deoxycytidine (5-Aza), suggesting that an epigenetic regulatory mechanism may be involved in 
RUNX3 silencing by hypoxia. Increased histone H3-lysine 9 dimethylation and decreased H3 acetylation 
in the RUNX3 promoter was observed upon hypoxic treatment of gastric cancer cells. Hypoxia caused 
upregulation of G9a histone methyltransferase and HDAC1. Overexpression of G9a and HDAC1 inhibited 
the nuclear localization and expression of RUNX3. The authors of this study proposed that hypoxia silences 
RUNX3 by epigenetic histone regulation during the progression of gastric cancer [47]. Moreover, 
overexpression of enhancer of zeste homologue 2 (EZH2) caused H3K27 trimethylation of the RUNX3 
promoter, which led to repression of RUNX3 expression in the absence of DNA methylation [48]. 
 
3.1.4. RUNX3 inactivation by protein mislocalization 
       Mislocalization of active nuclear RUNX3 protein to the cytoplasm was initially observed in 
gastric cancers [13], and followed by cancers of the breast [20,30] and liver (Quek T et al., unpublished 
data), and by colorectal polyps [31] and CRCs (Figure 2) [32, 106]. We noted that RUNX3 protein 
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accumulated in the nucleus of SNU16 cells after 6 hours of treatment with TGF-β, suggesting that RUNX3 
is translocated to the nucleus by TGF-β stimulation [13]. In a nude mouse assay, SNU16 cells stably 
expressing RUNX3(1-187), a truncated form of RUNX3, induced tumors that were larger than the control 
tumors formed  by parental cells expressing endogenous full-length RUNX3 [13]. Our results confirmed 
that RUNX3 was primarily confined to the cytoplasm of cells in RUNX3 (1-187)–induced tumors, whereas 
a substantial fraction of RUNX3 was present in the nucleus of cells in control tumors [13]. Our data 
suggest that cytoplasmic RUNX3 protein does not elicit tumor suppressive activity, and that it is therefore a 
novel mechanism of RUNX3 inactivation [13]. More recently, Kim et al (2009) [49] showed that 
Jun-activation domain-binding protein 1 (Jab1/CSN5) physically interacts with RUNX3 and facilitates 
chromosomal region maintenance 1 (CRM1)-dependent nuclear export. Subsequently, the sequestered 
RUNX3 protein in the cytoplasm is degraded through a proteosome-mediated pathway with the help of 
COP9 signalosome (CSN)-associated kinases. In contrast, Pim-1 phosphorylates four Ser/Thr residues 
within the Runt domain and thereby stabilizes the RUNX3 protein. In addition, it also alters the cellular 
localization of RUNX3 from the nucleus to the cytoplasm [50].  Pim-1 conferred stability to RUNX3, and 
Pim-1-induced cytoplasmic translocation of the RUNX3 protein could result in depletion of nuclear factors 
associated with RUNX3, thereby turning it into an oncogene [50]. Thus, it is intriguing that the function of 
RUNX3 as a cell fate regulator depends on its cellular localization. 
 
3.1.5. RUNX3 interaction with DNA repair protein Ku70 
       Using a proteomic approach, Ku70, a member of the DNA repair protein complex, was found to 
be bound to the transactivation domain of RUNX3, and was shown to interfere with RUNX3 transcription 
[36]. This was evident when RUNX3 markedly activated the transcription of p21, the target gene of Runx3, 
in Ku70 knockdown cells [36]. RUNX3 and Ku70 might regulate the cell cycle and balance cell growth by 
controlling p21 expression. Collectively, these data suggest a possible link between a tumor suppressor 
function and DNA repair, although further precise studies are needed to understand the significance of this 
interaction [36].  
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3.1.6. Role of RUNX3 in invasion, metastasis and angiogenesis of gastric cancer 
        RUNX3 transfection in gastric cancer cells resulted in TGF-β-induced anti-proliferative and 
apoptotic effects. In addition, inhibition of peritoneal metastases of gastric cancer in animals was also 
noted [38]. Microarray analysis of RUNX3 transfectants revealed upregulation or downregulation of genes 
involved in peritoneal metastasis related to cell adhesion (Sialyltransferase I, Annexins 5/7, galectin 4), 
signal transduction (vav3, MET, S100A11, MAPKK), apoptosis (caspase9) and immune responses (CD55 
and TLR1O). Thus, RUNX3 silencing affects the expression of critical metastasis-related genes that 
promote peritoneal metastasis of gastric cancers [38]. Furthermore, loss of RUNX3 expression correlated 
directly with increased vascular endothelial growth factor (VEGF) expression and tumor angiogenesis. 
Restoration of RUNX3 expression suppressed the angiogenic potential of gastric cancer cells, and 
correlated with downregulated VEGF expression via promoter repression in vitro, and attenuation of 
tumorigenicity and abrogation of metastasis in animal models [37]. Thus, RUNX3 negatively regulates the 
angiogenesis, growth and metastasis of gastric cancer. 
3.1.7. RUNX3, Helicobacter pylori and gastric cancer 
        Helicobacter pylori (H. pylori)-induced release of cytokines, reactive oxygen species and nitric 
oxide may hypermethylate CpG islands by activating DNA methyltransferase, as in the case of E-cadherin 
[51]. H. pylori-infected individuals exhibited increased promoter methylation, and were associated with an 
increased risk of gastric cancer compared with H. pylori-negative individuals [52]. Nakajima et al. (2009) 
proposed the existence of a methylation fingerprint of H. pylori in infected gastric mucosae. [53]. However, 
so far, only a solitary report exists that links methylation of the RUNX3 promoter with H. pylori infection 
in gastric cancers [54]. Persistent H. pylori infection in the middle and lower portions of the stomach has 
been shown to induce RUNX3 hypermethylation in the epithelial cells, which results in intestinal 





3.1.8. RUNX3 inactivation in preneoplastic gastric lesions 
       The non-neoplastic mucosa of the stomach, unlike that of other organs, exhibits frequent 
age-related RUNX3 methylation that is commonly seen in people above the age of 77 years [55]. Besides 
age-related methylation, increased field effect-related RUNX3 methylation was also observed in the 
residual gastric mucosa resulting from resection of a remnant stomach for gastric cancers, but not in that of 
an intact stomach. Thus, an evaluation of RUNX3 methylation status in normal gastric mucosa may provide 
an estimate of the risk for gastric carcinogenesis [56]. Li et al. (2002) showed that expression of RUNX3 
was reduced in some intestinal metaplasias [8], and gastric epithelial cells of Runx3-/-p53-/- mice also 
differentiated into intestinal-type cells [57, 58].  Other precursor gastric lesions, such as chronic gastritis 
[15] and gastric adenomas [15], also showed RUNX3 hypermethylation, indicating a role for RUNX3 in 
gastric cancer progression.  
3.2. Colorectal cancer 
3.2.1. RUNX3 attenuates oncogenic Wnt signaling in intestinal tumorigenesis 
       Inactivating mutations of the APC gene, which encodes a key regulator of the canonical Wnt 
pathway that destabilizes β-catenin, is a well-characterized mechanism of colonic carcinogenesis [59]. A 
recent discovery by our group provided evidence of cross-talk between these two pathways in intestinal 
tumorigenesis [32]. The intestinal epithelia of Runx3-/- mice showed increased proliferation and increased 
β-catenin/Tcf4 activity, as evidenced by the upregulation of target genes (CD44, cyclin D1, c-Myc, 
Axin2/conductin, and EphB2) activated by β-catenin. In HCT116 cells, endogenous β-catenin, TCF4 and 
RUNX3 coimmunoprecipitated, forming a ternary complex (Figure 3A). RUNX3 inhibited the DNA 
binding of β-catenin/TCF4 in vivo and vitro, and prevented transactivation of β-catenin/TCF4. Knockdown 
of endogenous RUNX3 in RUNX3-positive cells enhanced the binding of β-catenin/TCF4 to cyclin D1 and 
c-Myc promoters, whereas induction of exogenous RUNX3 in RUNX3-negative cells downregulated the 
binding of β-catenin/TCF4 to cyclin D1 and c-Myc promoters. These data confirmed that RUNX3 
attenuates oncogenic Wnt activity by interacting with β-catenin/TCF4. The Runx3+/- and ApcMin/+ BALB/c 
mice developed adenomas in the small intestine, but not in the large intestine. Adenomatous polyps of 
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ApcMin/+ showed loss of heterozygosity (LOH) of APC, and nuclear β-catenin accumulation, while Runx3+/- 
mice revealed downregulated Runx3 expression due to hypermethylation of the Runx3 promoter. In 
contrast, Runx3+/-ApcMin/+ double compound mice exhibited adenomatous polyps in the small and large 
intestines and adenocarcinomas in the small intestine at 65 weeks. The frequency of tumor formation, and 
the number and size of tumors were enhanced in the Runx3+/-ApcMin/+ mice compared to Runx3+/- and 
ApcMin/+ mice. Immunohistochemical analysis showed that the small adenomas of the Runx3+/-ApcMin/+ mice 
had either downregulated RUNX3 expression or nuclear β-catenin accumulation, but never both, indicating 
that biallelic inactivation of either Runx3 or Apc is sufficient for adenoma induction. However, large 
adenomas and adenocarcinomas display aberrant nuclear/cytoplasmic β-catenin accumulation in the 
Runx3+/- background, which suggests that alteration of both genes causes strong Wnt activation. Consistent 
with these observations in the mouse adenomas, human adenomatous polyps frequently revealed either 
nuclear/cytoplasmic β-catenin accumulation with nuclear RUNX3 expression or reduced RUNX3 
expression without β-catenin accumulation. However, in human colorectal adenocarcinomas, both RUNX3 
downregulation and nuclear/cytoplasmic β-catenin accumulation occur in a significant fraction of cases, 
suggesting that both RUNX3 inactivation and -catenin activation are necessary for the progression of 
adenomas to adenocarcinomas (Figure 3B). These results suggest that RUNX3 negatively controls the 
strength of Wnt signaling by stimulating physiological Wnt ligands or by APC inactivation or β-catenin 
activation, through RUNX3/β-catenin/TCFs ternary complex formation. We propose that RUNX3 
functions as a ‘brake’ in oncogenic Wnt signaling, and that RUNX3 inactivation is an initiator of adenoma 
formation, as is the alteration of APC in humans and mice [32]. 
3.2.2. Transducin enhancer of Split (Tle6-like/TLED) mediated the antagonism of RUNX3 in the 
progression of DNA mismatch repair-deficient colorectal cancers 
       Chen and co-workers (2008) [60] observed increased tumor multiplicity and increased frameshift 
and base-substitution mutations of Apc in Mlh3-, Pms2- and Apc- deficient mouse models. Tumor 
progression in these mice was also associated with amplification of the Transducin enhancer of Split gene 
(Tle6-like) amplicon on chromosome 12F2. Increased expression of Tle6-like or the human alternative 
spliced isoform (TLED) was observed in a subset of human CRCs with positive RUNX3 expression. 
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Expression of Tle6-like or the TLE6D splice isoform in colon cancer cells increased cell proliferation, 
colony-formation, cell migration and xenograft tumorgenicity. Coimmunoprecipitation assays 
demonstrated that TLED interacted with RUNX3, which resulted in the inhibition of RUNX3 target 
transactivation, thereby providing a selective growth advantage for cell proliferation and migration. 
However, the functional significance of this interaction in CRC progression is still unclear. 
 
3.2.3. RUNX3 inactivation in pre-invasive colorectal lesions of alternative carcinogenesis 
pathways 
       We examined RUNX3 inactivation in (A) the traditional adenoma-carcinoma sequence and (B) 
the serrated colorectal pathway [31]. We also assessed it in (C) the familial adenomatous polyps (FAP) 
(Figure 4). Pre-invasive lesions of the serrated colorectal pathway (B), such as hyperplastic polyps (15 of 
19, 79%) and traditional serrated adenomas (8 of 14, 57%), displayed significant downregulation of 
RUNX3 expression, compared to the normal colon samples (2 of 12, 16%) and sporadic traditional 
adenomas, pre-invasive lesions of (A), (3 of 17, 18%) (p<0.05). In FAP (C) specimens (n=19), aberrant 
crypt foci (78 of 91, 86%), small adenomas (25 of 40, 62%), and large adenomas (6 of 13, 46%) exhibited 
more frequent RUNX3 downregulation than did their adjacent normal mucosa (0 of 19, 0%) (all p<0.05). 
In all colonic carcinogenesis models (A-C), RUNX3 hypermethylation was more frequent in colorectal 
polyps (64 of 87, 74%) than in the normal colon (2 of 12, 16%) (p=0.001). The RUNX3 promoter had 
significantly more methylation in pre-invasive lesions of (B) (hyperplastic polyps, 17 of 19, 89%; and 
traditional serrated adenomas, 12 of 14, 86%) than in pre-invasive lesions of (A) (sporadic traditional 
adenomas, 7 of 17, 44%) (p=0.004), consistent with the frequent occurrence of DNA methylation in the 
polyps of the serrated neoplasia pathway [61]. However, the end-point histological lesions in (B), serrated 
adenocarcinomas, were not included in this study, and the RUNX3 promoter status in the late stages of 
serrated polyp pathway remains unknown. The RUNX3 promoter was hypermethylated in (C) FAP polyps 
(28 of 38, 74%). Hypermethylation correlated with RUNX3 silencing in (A and B) sporadic (27 of 36, 75%; 
p=0.022) and (C) FAP (21 of 28, 75%; p=0.021) polyps. 
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3.2.4. RUNX3 hypermethylation as a marker of the CpG island methylator phenotype in CRC 
       Approximately 20% of primary CRCs show promoter hypermethylation associated with 
transcriptional silencing [14, 32, 107, 108]. This cancer-specific epigenetic event has led to the inclusion of 
RUNX3 in a panel of five markers proposed to define a distinct subset of CRCs, termed the CpG island 
methylator phenotype (CIMP) [62]. This CIMP trait is tightly linked to microsatellite instability (MSI) and 
a high frequency of BRAF mutations in CRCs [62].  RUNX3 hypermethylation as a part of CIMP-positive 
CRCs has been correlated with a variety of molecular, clinical, histopathological and epidemiological 
features. A discussion of these features is beyond the scope of this review.   
3.3. Breast cancers 
3.3.1. RUNX3 inactivation by dual mechanisms of promoter methylation and protein 
mislocalization 
       Kim et al (2004) [15] and Suzuki et al (2005) [27] provided the first evidence that RUNX3 
hypermethylation is a characteristic of breast cancers. Besides RUNX3 hypermethylation, we demonstrated 
that protein mislocalization also contributes to RUNX3 inactivation (Figure 2). Using an in-house 
generated anti-RUNX3 monoclonal antibody, we demonstrated loss of RUNX3 function in the form of 
mislocalization of the RUNX3 protein [20]. The normal breast acini had unmethylated RUNX3 and showed 
strong nuclear RUNX3 expression, in contrast with the RUNX3-methylated cancer tissues. Extending our 
study to precursor breast lesions, we detected frequent instances of RUNX3 hypermethylation (75%, n=40) 
and loss of RUNX3 expression (88%, n=40) in ductal in situ carcinomas (DCIS) (Figure 4) [30]. In addition, 
copy number reductions [63] and LOH [64] in the RUNX3 region have also been reported to contribute to 
the loss of RUNX3 in breast cancers.  
3.3.2. Estrogen receptor signaling-mediated epigenetic RUNX3 inactivation in hormone 
receptor-positive breast cancers 
       Estrogen imprinting refers to acquisition of increased risk of breast cancer in adult life owing to 
early developmental exposure to endocrine disruptors. Cheng et al. (2008) [65] used mammospheres 
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containing enriched breast progenitor stem cells as an exposure system to simulate this imprinting 
phenomenon in vitro. The estrogen-exposed colonies formed out of these breast progenitors expressed 
nuclear estrogen receptor (ERα), whereas non-exposed colonies did not. Methylation microarray screening 
revealed increased hypermethylation, accounting for 0.5% (120) of CpG loci, including those found in the 
RUNX3 promoter, in epithelial cells derived from estrogen-exposed progenitors, compared to that in the 
non–estrogen-exposed control cells. Estrogen induced-RUNX3 hypermethylation was seen in both primary 
tumors and in the adjacent normal breast tissue, indicating that hypermethylation of RUNX3 is an early 
event in breast carcinogenesis. RUNX3 mRNA expression is negatively correlated with ERα expression in 
invasive ductal cancers. These data provide empirical evidence of a link between estrogen injury of breast 
stem/progenitor cells and carcinogenesis through estrogen-induced epigenetic changes. 
3.4. Esophageal cancers 
       Introduction of RUNX3 in SEG1, a Barrett’s esophagus-derived cell line unresponsive to TGF-β, 
led to a drastic increase in TGF-β antiproliferative activity and apoptotic induction, while transfection of 
RUNX3 in the absence of TGF-β had no effect on the proliferation and apoptosis of SEG1 cells. These 
results were the first to suggest that RUNX3 is essential for the antiproliferative and apoptotic effects of 
TGF-β in SEG1 cells [67]. Subsequently, frequent RUNX3 inactivation by promoter hypermethylation was 
noted in esophageal squamous cell carcinomas (ESCC) [68-70], adenocarcinomas (EAC) [12, 71], and 
Barrett’s metaplasia [12] and dysplasia [12]. RUNX3 induces Bim expression and enhances sensitivity to 
radiation and TGF--induced apoptosis in ESCC cells, thereby acting as an important determinant of 
radiosensitivity [69]. RUNX3 promotes radiosensitivity, while its inactivation promotes radioresistance 
[69]. 
 
3.5. Hepatobiliary and pancreatic cancers 
       In hepatocellular carcinoma (HCC), promoter hypermethylation and LOH of RUNX3 were 
frequently detected [72-77]. However, the frequency of LOH at RUNX3 (37.8%, n=37 [72] and 34.6%, 
n=26 [77], respectively) was less than the frequency of methylation (48.4%, n=62 [77] and 75.6%, n=41 
[72], respectively), and the majority of methylated cases exhibited LOH, suggesting that LOH at RUNX3 
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and hypermethylation of the RUNX3 promoter are common mechanisms of RUNX3 inactivation in 
hepatocarcinogenesis [72]. In our experience (T. Quek, unpublished data), normal liver tissues displayed 
nuclear RUNX3 expression in more than 80% of the hepatocytes. In contrast, 21 of 34 (62%) of HCCs 
displayed inactivation of RUNX3, of which 6 (29%) showed complete negativity, while 15 (71%) revealed 
cytoplasmic mislocalization of the RUNX3 protein, in both methylated and non-methylated samples 
(Figure 2). RUNX3 hypermethylation was observed in 3 of 6 (50%) RUNX3-negative cases, whereas none 
of the matched non-neoplastic liver samples exhibited methylation. Additionally, in a recent study, RUNX3 
methylation as a single molecular marker was demonstrated to be sensitive and specific in detecting 45% 
and 90% (n= 20) of well differentiated HCCs, 21% and 89% (n=28) of small HCCs (less than 3 cm) and 
29% and 91% (n=35) of early HCCs (TNM stages I and II) [76]. RUNX3 hypermethylation is also a marker 
of clonality in multicentric HCCs, thus distinguishing multicentric HCCs from a true clinical relapse [74]. 
RUNX3 hypermethylation is also seen in chronic hepatitis and non-cancerous liver tissues of both 
HCV-positive and HCV-negative HCC cases, but is absent in normal liver tissues [75].  
       Loss of RUNX3 expression due to promoter hypermethylation was seen in 7 of 10 (70%) bile duct 
and 9 of 12 (75%) pancreatic cancer cell lines [18]. About 56.8% (n=37) of primary biliary tract cancers, 
including cancer of the bile duct, gallbladder, and duodenal ampulla, also showed RUNX3 
hypermethylation [17]. Tumor-specific methylation of RUNX3 was also noted in pure primary gallbladder 
carcinomas [16]. RUNX3 expression was restricted to islets in the normal pancreas. Increased RUNX3 
expression was observed in chronic pancreatitis, while loss of expression was noted in primary and 
metastatic cancers [78]. These results portray a possible tumor suppressor role for RUNX3 in biliary tract 
and in pancreatic cancers. 
 
3.6. Tumors of the urinary tract and of male and female reproductive system 
       RUNX3 hypermethylation was seen in 73% (n=124) of primary bladder cancers and 86% (n=7) of 
tumor cell lines [80]. Normal bladder tissues did not show RUNX3 hypermethylation, and RUNX3 
methylation was not found to be age-related. Two patients with point mutations of RUNX3 also contained a 
wild-type RUNX3 allele, indicating that haploinsufficiency of RUNX3 increases the risk of bladder cancer 
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[80]. The in situ hypermethylation of RUNX3 in preneoplastic lesions, such as cystitis cystica and 
multifocal carcinoma, indicates that RUNX3 hypermethylation occurs early in bladder tumorigenesis, and 
accumulates irreversibly in bladder stem cells, which may eventually progress to cancer [82]. In prostate 
cancers, RUNX3 hypermethylation was detected in 32.4% (n=37) of prostate cancers and 14.3% (n=14) of 
prostatic intraepithelial neoplasia (PIN), and was absent in normal/benign prostatic tissue [21], indicating 
the involvement of RUNX3 in multistep prostatic carcinogenesis.  
       Ovarian granulosa cell tumors showed methylation of FHIT (28%, n=25), FNACF (24%, n=25), 
Cyclin D2 (12%, n=25), BRCA2 (4%, n=25) and RUNX3 (56%, n=25) [22]. Promoter hypermethylation 
correlated with gene silencing in tumor cell lines [22]. In contrast, the overexpression of RUNX3 in 
epithelial serous ovarian carcinomas, compared to expression in normal ovarian epithelium, suggested a 
possible oncogenic potential for RUNX3 [23]. Although RUNX3 mRNA levels were higher in these 
tumors than in normal ovarian epithelium, immunohistochemical analysis revealed that RUNX3 was 
expressed in the cytoplasm and not in the nucleus. As mislocalized RUNX3 is considered to be an inactive 
protein [13], the oncogenic role of RUNX3 in these tumors is not clear [23]. In infantile testicular yolk sac 
tumors, deletion of the distal 1p spanning 1p36 is relatively frequent, differentiating these types of tumors 
from their adult counterparts. Further investigation confirmed that both RUNX3 hypermethylation and 
LOH at 1p36.1 were very frequent in infantile testicular yolk sac tumors [24].  However, normal testis 
and testicular intratubular germ cell neoplasias, which are precursors of germ cell tumors, did not have 
hypermethylated RUNX3 [85].  
3.7. Lung cancers 
       Among the human non-small cell lung carcinoma (NSCLC) samples, p16 methylation was more 
frequent in squamous cell carcinomas than in adenocarcinomas. In contrast, APC [26] and RUNX3 [86,87] 
were frequently methylated in cases of adenocarcinoma. Thus, differential gene methylation contributes to 
the development of different lung cancer phenotypes. In addition, RUNX3, one of the genes identified in a 
panel of Wnt antagonists, such as APC, DKK1, DKK3, LKB1, SFRP1,2,4,5 and WIF1was methylated in 
28.3% (n=46) of normal lung tissues, and in 28.1% of low (n=32) and 70.8% (n=24) of high grade atypical 
adenomatous hyperplasias, which are supposedly precursors of lung adenocarcinoma [88]. These findings 
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indicate a role for RUNX3 inactivation in primary lung cancer development and progression, especially of 
glandular neoplasia of lung.  
3.8. Central nervous system and Skin tumors 
        Glioblastomas have a grave prognosis, and are the most aggressive, most common, and least 
treatable form of malignant gliomas. They are known to exhibit aberrant DNA methylation [92]. A solitary 
report, which involved the pharmaceutical unmasking of epigenetic alterations with 5-aza-dC, coupled with 
a cRNA microarray analysis, in tumor cell cultures, showed that both RUNX3 and Testin harbored frequent 
tumor-specific methylation in primary glioblastomas [28].  However, the functional importance of 
methylation of RUNX3 in glioblastomas remains unclear.  
        Deregulation of downstream molecules of sonic hedgehog signaling (Shh) [93] and Wnt 
signaling [94] pathways has been implicated in BCCs. In the context of these findings, we tested the 
expression of RUNX3 and β-catenin, the downstream effectors of the TGF-β/BMP (bone morphogenic 
protein) and Wnt pathways, respectively, in BCCs. We found that almost all (100%, n=75) BCCs 
overexpressed RUNX3 in the nucleus. Nuclear β-catenin accumulation was seen in 41% (n=75) of BCCs in 
contrast to the basal cells of normal skin, which displayed mainly membranous expression and lacked 
nuclear reaction to β-catenin. The latter data suggested aberrant Wnt activation in a subset of BCCs [34]. 
Taken together, our results indicate an oncogenic role for RUNX3 in BCCs, and also suggest a possible 
oncogenic interaction between the TGF-β/BMP pathway and Wnt signaling in promoting tumorigenesis. 
On the other hand, RUNX3 mRNA expression was downregulated in majority of primary (100%, n=82) 
and metastatic (100%, n=41) cutaneous melanomas compared to normal skin suggesting a tumor 
suppressor role of RUNX3 in melanoma progression [91]. However, promoter hypermethylation 
contributed to loss of RUNX3 expression in a very less proportion of primary (4%, n=52) and metastatic 
(17%, n=30) cutaneous melanomas [91]. Instead,  a microRNA (miR-532-5p) identified as a target of 
RUNX3 mRNA sequences was  significantly up-regulated in melanoma lines and metastatic melanoma 
tumors relative to normal melanocytes and primary melanomas, respectively. On analyzing the relation 
between RUNX3 and miR-532-5p, it was noted that inhibition of miR-532-5p up-regulated both RUNX3 
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mRNA and protein expression [91]. This data suggest that the expression of tumor suppressor RUNX3 in 
cutaneous melanomas is regulated by miR-532-5p [91]. 
3.9. Oral, salivary gland and head and neck cancers 
       RUNX3 was weakly expressed in normal oral epithelia, but strongly expressed in dysplastic oral 
squamous epithelia, which develop into oral squamous cell carcinoma [95]. RUNX3 expression was noted in 
the cytoplasm of the upper and middle layers of normal and dysplastic squamous mucosa, and in the cancer 
cells around the cancer pearls of invasive squamous cell carcinomas. RUNX3 expression was associated 
with well-differentiated squamous cell cancers, and was absent in the poorly differentiated subtype. In 
contrast, cell proliferation, as assessed by expression of the Ki-67 protein, had an inverse correlation with 
differentiation in these cancers [95]. In all normal adult salivary glands, RUNX3 was detected in the nuclear 
and cytoplasm of both ductal and serous or mucous acinous cell, as well as in a few lymphoid cells, but not in 
the myoepithelial cells [96]. In adenoid cystic carcinomas (ACC), RUNX3 was detected mainly in the 
cytoplasm, and not in the nucleus. In cases of perineural, intraneural, and perivascular invasion in ACC, both 
tumor cells and nerve cells showed RUNX3 cytoplasmic immunopositivity. ACC cells in tumors invading 
the normal salivary gland tissue displayed cytoplasmic mislocalization or even loss of RUNX3 expression, 
indicating RUNX3 inactivation in the invasive ACC cells [96]. Similar to BCCs of the skin, Tsunematsu et al 
(2009) demonstrated an oncogenic role of RUNX3 in head and neck squamous cell carcinomas (HNSCCs) 
[35]. Compared to normal oral mucosal cells in which only a few basal epithelial cells expressed nuclear 
RUNX3, most primary HNSCC tissue cells overexpressed nuclear RUNX3 protein, also confirmed by 
fractionated-western blot analysis in HNSCC cell lines [35]. Further, the authors showed that ectopic 
RUNX3 overexpression promoted cell growth and inhibited serum starvation-induced apoptosis and 
chemotherapeutic drug induced apoptosis in HNSCC cells, confirmed by RUNX3 knockdown models. 
Moreover, RUNX3 overexpression enhanced tumorsphere formation [35]. All these findings suggested 
RUNX3 as a potential oncogene in HNSCCs. It is interesting to speculate that this distinct oncogenic 
function in HNSCCs and skin BCCs may be accounted for by the pathogenesis of both types of 
cancer, which arise from squamous epithelium. 
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4. The RUNX3 promoter 
        The regulation of RUNX3 by two promoters may influence its epigenetic silencing. The P2 
promoter is located within a conserved CpG island (4. 2 kb), while the P1 promoter occurs in a CpG-poor 
environment [97], and is hence unlikely to be a target of methylation. RUNX3 methylation is reported to 
occur initially in a high frequency (96%) of neoplastic and non-neoplastic gastric mucosas, in the 5’-most 
region of the promoter, and to spread to the transcription start site, where it is relatively less frequent (53% 
of gastric cancers and 11% of non-neoplastic gastric mucosas), but is specific and critical for gene 
silencing [109]. Thus, analysis of RUNX3 methylation at multiple regions within the RUNX3 CpG island 
may be used to assess the risk for gastric cancer.  
5. Anti-RUNX3 antibodies 
       Some controversial reports have questioned the role of RUNX3 as a tumor suppressor in 
gastrointestinal carcinogenesis, largely due to the failure to demonstrate RUNX3 expression in the 
gastrointestinal epithelium [110]. This discrepancy partially stemmed from the use of a specific RUNX3 
antibody (G-poly), originally used by Levanon et al. (2001), to detect the Runx3 protein in mice [111]. 
Recently, we resolved this controversy by a comparative validation of G-poly versus a panel of in-house 
generated anti-RUNX3 mouse clones (R3-1E10, R3-3F12, R3-10C7 and R3-8C9) and a commercial 
polyclonal RUNX3 rabbit antibody (Active Motif) [104] in mouse gastrointestinal cells [112]. Monoclonal 
antibodies R3-1E10, R3-3F12, R3-10C7 and R3-8C9 reacted only with RUNX3/Runx3. In contrast, G-poly 
reacted with RUNX3/Runx3 most strongly, but also cross-reacted significantly with RUNX1/Runx1 and 
RUNX2/Runx2. The antibodies recognizing the RUNX3 N-terminal region (residues 1–234: R3-1E10 and 
R3-3F12 detected RUNX3 region 188-234; Active Motif detected RUNX3 region 28 to 53) reacted with 
gastric epithelial cells immunohistochemically, whereas those recognizing the C-terminal region (beyond 
residue 234) such as R3-10C7, R3-8C9, and G-poly did not [112]. This pattern suggests that the C-terminal 
region of Runx3 in the gastrointestinal epithelium is specifically modified or masked by cellular proteins that 
bind to Runx3 only in this tissue. 
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6. Clinical and morphomolecular correlates of RUNX3  
       In gastric cancers, the intestinal rather than the diffuse type exhibits frequent RUNX3 
hypermethylation [98]. RUNX3 hypermethylation was associated with nuclear MSI-high (nMSI-H) and 
mitochondrial MSI (mtMSI) status, suggesting that RUNX3 is an important epigenetic target in the 
evolution of nMSI-H and mtMSI gastric cancers [99]. Also, RUNX3 expression correlated with the chief 
cell phenotype [100] and intestinal phenotype [101] in gastric cancers. In CRCs, the poorly differentiated 
carcinomas displayed more frequent RUNX3 hypermethylation than did the well-differentiated ones [102]. 
RUNX3 hypermethylation was more frequent in MSI-high than in microsatellite stable (MSS) CRCs [14]. 
Furthermore, transforming growth factor-β receptor type II (TGFBR2) mutations correlated directly with 
CIMP-high status, and indirectly with RUNX3 hypermethylation in MSI-H sporadic CRCs [103]. Unlike 
CRCs, well-differentiated ESCCs exhibited more RUNX3 hypermethylation than did moderately and 
poorly differentiated ones [70]. RUNX3 and CDKN2A methylation were higher in EACs than in high 
grade-dysplastic Barrett’s [71]. In breast cancers, RUNX3 hypermethylation correlated with ER [27, 30] 
and PR [30] positivity in hormone-receptive cancers. This correlation of RUNX3 methylation with ER 
reactivity may possibly be attributed to ER-induced RUNX3 hypermethylation, as discussed earlier. In 
HNSCCs, frequent RUNX3 expression correlated with malignant behavior such as poor differentiation, 
invasiveness and metastasis [35]. In HCCs, RUNX3 hypermethylation was frequently found in 
HCV-positive tissues [72,75]. Furthermore, we observed that nuclear RUNX3 expression in HCCs 
correlated significantly with alcohol use (p = 0.039) (T Quek, unpublished data). HCCs associated with 
alcoholism have significantly more alterations of the Rb1 and p53 pathways than do those caused by HCV 
[113]. It is interesting to speculate about the possible link between TGF-/RUNX3 and Rb1 and p53, in the 
context of HCC. In bladder tumors, methylation of RUNX3 increases with age and occurs at an early stage 
of tumorigenesis. RUNX3 methylation may be used as a “molecular clock” to determine the “age” of the 
tumors. Using the RUNX3 methylation-based molecular clock, bladder cancers in smokers are “older” than 
those of non-smokers [82]. It is possible that the tumors of smokers divide quickly and accumulate more 
methylation errors than do those of non-smokers, or that the tumors of smokers are initiated at an earlier 
age.  
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A summary of the clinical and morphomolecular association between RUNX3 and different cancer types is 
provided in Table 2. 
7. Prognostic associations of RUNX3 
        RUNX3 inactivation has been frequently, but not unequivocally, linked with a poor prognosis of 
esophageal [68-70], gastric [101,104, 116], colonic [106] and lung cancers [87, 89, 90] (Table 3).  
       In gastric cancers, positive RUNX3 expression correlated with longer overall survival, whereas 
loss of expression correlated with poor survival [104, 116]. In CRCs, RUNX3 (as one of the component of 
the CIMP panel of genes) hypermethylation, correlated with poor survival of patients suffering from MSS 
tumors [105]. Reduced expression of active RUNX3 protein in the nucleus, and increased amounts of 
inactive RUNX3 protein mislocalized to the cytoplasm were frequently detected in the advanced stages 
(III/IV) of CRCs [106]. In bladder cancers, RUNX3 hypermethylation is associated with a 100-fold 
increase in cancer risk, tumor stage and recurrence [80]. It also appears to be associated with muscle 
invasion, tumor progression and overall and cancer-specific survival [81]. In ESCCs, RUNX3 had a 
significant impact on patient prognosis, with worse survival in the RUNX3-negative group [68, 70]. In 
early ESCCs (stage T1/T2), the prevalence of lymph vessel invasion and the number of metastatic lymph 
nodes were significantly higher in RUNX3-negative tumors [68]. Loss of RUNX3 expression also 
correlated with poor survival in breast [66] and oral [95] cancers and in ACC of the salivary gland [96]. 
8. Diagnostic and predictive implications 
        The key feature in favor of including RUNX3 in a diagnostic or predictive panel of cancer 
biomarkers is the high specificity of RUNX3 inactivation in tumor tissues relative to normal tissues. Loss 
of RUNX3 expression, specifically in breast cancers [20, 30], and its positive expression in normal/benign 
breast tissues [20, 30] suggest that RUNX3 is a potential immunohistochemical marker for use in 
diagnostic histopathology. As a predictive marker, assessment of RUNX3 expression in pretreatment 
esophageal biopsies of ESCC may predict a patient’s sensitivity to radiotherapy [69]. Genetic variants of 
RUNX3 (single-nucleotide polymorphisms; SNPs) have been associated with smoking and risk prediction 
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in primary urinary bladder cancers [115]. The SNP7 rs760805 AA genotype is linked to carcinogenic risk. 
Multifactor dimensionality reduction analysis identified SNP3 rs11249206, SNP5 rs1395621, SNP7 
rs760805, SNP8 rs2236852 and the trichotomized cumulative smoking as five factors best associated with 
a more than six-fold risk for bladder cancer [115].  Besides bladder cancers, based on a single-locus 
analysis, RUNX3 SNPs such as SNP3 rs11249206 CC, SNP7 rs760805 AA and SNP8 rs2236852 GG were 
found to be associated with increased gastric cancer risk in a Chinese population [117]. A further combined 
analyses of these three SNPs revealed that the combined genotypes with four to six variant (risk) alleles 
(SNP3 C, SNP7 A, and SNP8 G alleles) were associated with an increased risk of gastric cancer compared 
with those with one to three variant (risk) alleles and this risk was more specifically observed among 
patient groups of age >/=65 years, never smokers and drinkers [117].  Other implications of RUNX3 in 
cancer detection and prediction include the following: Methylation of RUNX3 as a part of an 11-gene panel 
was detected in urine sediments of bladder cancer patients. Seventy-five percent of stage 0a and 88% of 
stage 1 diseases were detected by methylation-specific PCR for this set of genes [83]. Since RUNX3 
hypermethylation is an early event in tumorigenesis, its detection in urine or biopsy specimens could serve 
as a marker to screen at-risk populations of cigarette smokers before onset of any symptoms [82]. Frequent 
RUNX3 methylation in colorectal polyps could suggest its possible inclusion in the currently existing panel 
of epigenetic markers (CDKN2A, MGMT, MLH1, SFRP2) for detection of CRCs and its precursors from 
fecal samples [118].  
 
9. Therapeutic implications 
        Reversal of DNA methylation by demethylating agents and inhibitors of 
DNA-methyltransferases (DNMTs) restores gene expression and function. Using either genetic or small 
interfering ribonucleic acid (siRNA)-mediated knockout strategies, inhibition of DNMT1 has been found 
to demethylate and reactivate RUNX3, as well as the cancer-related genes, CDKN2A, RASSF1A, HTLF and 
AKAP12B, in gastric cancer cells [119]. Runx3 expression was noted to be reduced in Dnmt3b 
overexpressing transgenic ApcMin/+ mice, which showed increased tumorigenesis [120]. It is interesting to 
speculate that if Runx3 were a target of Dnmt3b, then targeted-inhibition of Dnmt3b would be a promising 
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therapy for arresting CRC progression at its early stages (Figure 3A). RUNX3-negative gastric cancer cell 
lines treated with Vorinostat (suberoylanilide hydroxamic acid), a new class of HDAC inhibitor, 
reactivated RUNX3, causing inhibition of tumor growth and apoptosis induction [121]. Enforced RUNX3 
expression in gastric cancer cell lines caused downregulation of cyclin D1 and upregulation of p27, and 
caspases 3,7 and 8, leading to apoptosis and eventual inhibition of tumor growth and metastasis [104, 116]. 
Furthermore, RUNX3 is a marker of chemosensitivity. RUNX3 overexpression sensitized gastric cancer 
cells to chemotherapeutic drugs by downregulating Bcl-2, MDR-1, and MRP-1[122], while in HCC, 
RUNX3 in combination with adriamycin enhanced caspase-8 and inhibited Bcl-2 and suppressed tumor 
growth in vivo and in vitro [123]. Similar observations were also noted with CRCs [114]. Together, the 
above results suggest that RUNX3 may be an effective therapeutic target for gastric, hepatic and colonic 
cancers. 
10. Future perspectives 
        The RUNX family of genes, RUNX1, RUNX2 and RUNX3, are heavily involved in the cancer 
process [125]. In mouse model systems, Runx family genes are known to act as dominant oncogenes. 
Ectopic expression of Runx genes might perturb cell differentiation but lead to growth arrest, and it seems 
that full oncogenic transformation can only take place when overexpression of Runx genes is combined 
with alterations in the growth-arrest pathway or when Runx genes collaborate with other oncogenes. 
Interestingly, overexpression of RUNX3 was observed in BCC, a type of skin cancer known to be 
associated with deregulated Sonic hedgehog signaling, in which -catenin was concomitantly found to 
accumulate in nuclei [34]. This observation suggests that overexpressed RUNX3 has an oncogenic 
influence in the aberrant signaling of hedgehog and Wnt. Mutations of the genes encoding components of 
various signaling pathways, including Notch, Wnt, Hedgehog, TGF/BMPs, and RTKs, have been 
associated with cancers, either as oncogenes (dominant-active versions of the proteins) or as tumor 
suppressor genes (revealed as recessive mutations) [126]. RUNX3 is a novel node between tumor 
suppressive TGF/BMPs and oncogenic Wnt signaling [32], both of which are known to regulate the 
function and development of adult epithelial stem cells and so-called cancer stem cells. To maintain stem 
cell functions, multipotency and self-renewal capacity in the microenvironment, RUNX3 might have to 
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behave as an oncoprotein in a context-dependent manner. 
11. Conclusions 
        RUNX3 is deeply involved in multiple cancer processes, such as cell growth, apoptosis, 
angiogenesis, metastasis, most likely epithelial-mesenchymal transition (EMT), and cancer stem cell 
development, in various types of tissues. Identification of key tissue- and stage-specific target genes of 
RUNX3 functioning as a tumor suppressor or an oncogene is an important step forward, and combination 
of these genes would improve the potential of usage of RUNX3 as a biomarker for cancer diagnosis. An 
understanding of the upstream and downstream signaling pathways of RUNX3 in the context of 
physiological and pathological processes is indispensable if we are to harness our growing knowledge of 
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Information for this Review was compiled by searching the PubMed database for articles published until 
May 2009. Only articles published in English were considered. Search terms included “RUNX3” and 
"cancer", in association with the terms “gastric”, “colorectal”, hepato biliary”, “prostate”, “esophageal”, 
“urinary bladder”, “lung”, ”ovary”, “testicular”,  “cerebral”, “prognosis”, “progression”, “carcinogenesis”, 
“survival”, “biomarker”, “clinicopathology” and “chemotherapy”. Full articles were retrieved, and further 
information was obtained from relevant references. We focused on relevant primary literature rather than 
review papers to compile this review. In cases where multiple references supported an individual statement, 
the most recent reference was cited. A specific emphasis was placed on literature focusing on molecular 
mechanisms and frequency of RUNX3 hypermethylation and protein expression in solid tumor and cancer 














Figure 1. RUNX3 transactivation in gastric carcinogenesis.  
Downstream of transforming growth factor (TGF)-β signalling, RUNX3 transactivates target genes 
synergistically with Smads and P300. RUNX3 positively regulates the expression of Bim and p21, and 
negatively regulates VEGF, and thereby affects apoptosis, cell growth arrest, and angiogenesis, 
respectively. CBFβ/PEBP2β is a non-DNA-binding partner of RUNX, and confers high DNA-binding 
affinity and stability to RUNX. FoxO3a interacts with RUNX3 to activate Bim and Ku70, a DNA 
repair-related protein that inhibits transactivation of RUNX3. EZH2 downregulates RUNX3 expression by 
increasing histone H3 methylation on the RUNX3 promoter.  
Figure 2. Mislocalization of RUNX3 protein to the cytoplasm represents an alternative mechanism of 
RUNX3 inactivation in human neoplasms 
Representative histopathological images of mislocalized RUNX3 in human cancers. Nuclear localization of 
RUNX3 in normal tissues of colorectal (A) and gastric (D) epithelium, breast lobules (G), and liver (J). 
Inset in D indicates strong expression of RUNX3 in the chief cells (black arrow) compared to weak 
staining in the parietal cells (red arrow). Mislocalization of RUNX3 in the cytoplasm of sporadic colorectal 
adenomatous polyps (B) and adenocarcinomas (C), intestinal metaplasia (E) and adenocarcinoma (F) in 
stomach, ductal carcinoma in situ (H) and invasive ductal carcinoma (I) in breast, and hepatocellular 
carcinomas (K). A to F, original magnification x 1000; G to K, original magnification x 400; inset in D, 
original magnification x 1000.  
Figure 3. RUNX3 attenuates oncogenic -catenin/TCFs in intestinal tumorigenesis  
(A) A ternary complex between RUNX3 and -catenin/TCFs functions as a ‘node’ downstream of 
oncogenic signaling of Wnt and tumor suppressive signaling of TGF-/BMPs. The complex formation 
inhibits upregulation of cyclin D1, EphB2, AXIN2, c-Myc and CD44 by -catenin/TCFs, and p21 by 
RUNX3. TLE6D, a transcriptional co-regulator, directly antagonizes RUNX3 transactivation. RUNX3 is 
repressed via promoter hypermethylation by EZH2, and most likely also by DNMT3b. 
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(B) Inactivation of either RUNX3 or APC can induce colonic adenomas in mice and humans. Runx3+/- and 
ApcMin/+ BALB/c mice develop the same number and size of small intestinal adenomas. Small adenomas 
(initiation of adenoma formation) in the Runx3+/-ApcMin/+ double compound mice have either 
downregulated Runx3 expression or nuclear β-catenin accumulation, but never both, indicating that 
biallelic inactivation of either Runx3 or Apc is sufficient for adenoma induction. This feature is consistent 
with human adenomatous polyp cases. In contrast, Runx3+/-ApcMin/+ double compound mice develop 
adenomas in the small and large intestines, and adenocarcinomas in the small intestine. Large adenomas 
and adenocarcinomas of both mice and humans displayed aberrant nuclear/cytoplasmic β-catenin 
accumulation, and reduced RUNX3 expression, which suggests that alteration of both genes causes strong 
Wnt activation. Thus, inactivation of both RUNX3 and APC is necessary for the progression of adenomas 
to adenocarcinomas.  
Figure 4. RUNX3 inactivation is an early molecular event in colonic and breast carcinogenesis  
In colon cancers, the familial adenomatous polyposis (FAP) and sporadic traditional adenomas (sTA) 
develop according to the traditional adenoma-carcinoma sequence (AD-CA), whereas the serrated polyps, 
such as hyperplastic polyps (HP) and traditional serrated adenomas (TSA), follow the serrated-polyp 
neoplasia pathway, with increasing DNA hypermethylation. FAP showed frequent RUNX3 inactivation by 
promoter hypermethylation in the aberrant crypt foci (ACF), the earliest dysplastic lesion formation. sTA 
had levels of RUNX3 inactivation that were comparable to those in small (SmAd) and large adenomas 
(LAd) of FAP. In contrast, RUNX3 inactivation was more frequently accompanied by promoter 
hypermethylation in HPs and TSAs, than in sTAs, which is consistent with the hypothesis that increasing 
and progressive DNA methylation is an early molecular event in the evolution of serrated colorectal polyps. 
The status of RUNX3 in serrated adenocarcinomas is still unknown. In breast cancers, RUNX3 inactivation 
by frequent promoter hypermethylation and protein mislocalization is often detected in ductal carcinoma in 
situ (DCIS) and invasive ductal carcinoma (IDC), suggesting that the promoter hypermethylation and the 
protein mislocalization are early events in breast cancer progression. RUNX3 methylation is more frequent 
in estrogen-exposed progenitor cells than in the non–estrogen-exposed control cells. This suggests a 
possible link between estrogen injury of breast stem/progenitor cells and carcinogenesis, through 
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estrogen-induced epigenetic changes.  
 
Table 1  RUNX3 inactivation in human cancers 
A.  In Cancers 
Cancer Site Histological Subtype 
RUNX3 Methylation Reduced RUNX3 Expression
Reference Percentage 
(%) 




Total no. of 
cases (n) 












 EAC 73 37   [71] 
Gastric AC   56 102 (IHC) [100] 
    39 95 (1HC) [116]  
    83 97 (IHC) [101] 
  53 57   [54] 
  55 40   [99] 
    49 120 (IHC) [37] 
    44 97 (IHC) [13] 
    30 86 (IHC) [104] 

















































  5 61   [15] 
  34 92   [102] 
  20 30   [105] 
  20 920   [108] 
  33 45 29 48 (IHC) [32] 
 






    26 849 (IHC) [106] 
Hepatic  HCC 48 62   [77] 
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  48 19   [74] 












  [76] 
  50 6 62 34 (IHC) Unpublished 
Gallbladder AC 32 50   [16] 
  22 9   [17] 
Bile duct AC 78 23   [17] 
  70 10 (CL) 70 10 (CL) (PCR) [18] 
Duodenal 
Ampullary 
AC 20 5   [17] 
Pancreas AC 75 12 (CL) 75 12 (CL) (PCR) [18] 
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  42 57   [27] 
  71 118   [81] 









  [83] 
Breast IDC 25 25   [15] 
























  87 15 65 88 (IHC) [66] 
  76 21 91 23 (IHC) [30] 
Prostate AC 32 37   [21] 
  23 44   [15] 
  10 50   [27] 







33 6 (CL) (PCR) [22] 






  [24] 
 GCT 2 55   [85] 
Uterus and 
adnexa 












  [15] 
 SCC cervix 2 82   [124] 
Lung Total NSCLC 
ADC 
SCC 









  [26] 
 Unknown 46 24   [15] 
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19 31 (CL) [87] 
 ADC    48 98 (IHC) [89] 









































 NSCLC 25 101   [90] 
 NSCLC 89 19   [88] 
Brain Glioblastoma 56 32 (CL)   [28] 












































































Table 1  RUNX3 inactivation in human cancers 




RUNX3 Methylation Reduced RUNX3 Expression 
Reference Percentage 
(%) 
Total no. of 
cases (n) 
Percentage (%)


















  [88] 
Prostate PIN 14 14   [21] 
 BPH 0 30   [84] 









  [15] 










  [73] 
 HCV+ NL-HCC 24 46   [75] 
Gallbladder Chronic cholecystitis 0 25   [16] 
Colon sTA  48 35 29 35 (IHC) [32] 









































Breast DCIS 75 40 88 40 (IHC) [30] 
NSCLC, non small cell lung cancer; ADC, Adenocarcinoma of lung; SCC, squamous cell carcinoma of lung; ADSC. Adenosquamous 
lung carcinoma; SCLC,   small cell lung carcinoma of lung;  LC, large cell carcinoma of lung; IHC, immunohistochemistry; PCR, 
polymerase chain reaction; CL, cell line; NB, northern blot; ISH, in situ hybridization; EAC, esophageal adenocarcinoma; ESCC, 
esophageal squamous cell carcinoma; AC, adenocarcinoma; HCC, hepatocellular carcinoma; TCC, transitional cell carcinoma; IDC, 
invasive ductal carcinoma; DCIS, ductal carcinoma in situ; GCT, granulosa cell tumor; SEC, serous epithelial carcinoma; YST, yolk sac 
tumor; BCC, basal cell carcinoma; BE, Barrett's esophagus; LGD, low grade dysplasia; HGD, high-grade dysplasia; IM, intestinal 
metaplasia; PIN, prostatic intraepithelial neoplasia; sTA, sporadic traditional adenoma; HP, hyperplastic polyp; TSA, traditional serrated 
adenoma; FAP, familial adenomatous polyposis; ACF, aberrant crypt foci; SmAD, small adenoma; LAd, large adenoma; AAH, atypical 
adenomatous hyperplasia; *, indicates 62 total HCCs (44 HCV+ and 18  HCV-); BPH, benign prostate hypertrophy; ADSCC, 
adenosquamous cell carcinoma; HCV+NL-HCC, HCV positive non neoplastic liver tissue from HCC patients; WDHCC, well-




Table 2 Clinical and morphomolecular associations of RUNX3 in human cancers 
Tumor type Assay Patient cohort Association Reference 
Gastric IHC GC, surgically treated, n=102 RUNX3 expression associated with chief cell phenotype in normal and malignant gastric mucosa [100] 
 IHC GC, surgically treated, n=95 
Loss of RUNX3 expression was more frequent in diffuse and mixed type cancer than intestinal 
type cancer 
[116] 




GC, surgically treated, n=100 Significant RUNX3 methylation seen in nMSI and mtMSI GCs compared to MSS and mtMSS GCs [99] 
Colonic MSP Sporadic CRC, surgically treated, n=92 RUNX3 methylation associated with poorly differentiated adenocarcinomas [102] 
 MSP Sporadic CRC, surgically treated, n=91 RUNX3 hypermethylation was common in tumors with high frequency of  MSI-H status [14] 
 PCR /MethyLight MSI-H sporadic CRC, n=144 





MSP HCC, surgically treated, n=41 RUNX3 methylation correlated positively with HCV positive status and capsule formation in HCCs [72] 
 IHC HCC, surgically treated, n=34 Nuclear RUNX3 expression correlated with alchoholism Unpublished 
 COBRA 
Total: 176 liver tissues (77 HCCs and matched non-
cancerous liver tissues) and 22 normal liver tissues 




Biliary tract (BDCa, n=23; GBCa, n=9 and AMPCa, 
n=5) 
Patients of biliary tract tumors with methylated RUNX3 promoter were significantly older than 
those with unmethylated RUNX3 promoter 
[17] 
Esophageal qRT-MSP  EAC, n=37, BE, n=47 RUNX3 methylation significantly higher in EAC than BE [71] 
 IHC ESCC,surgically treated, n=144 




Endoscopic biopsy samples of EAC, n=77, BE, 
n=93, NE, n=64 
RUNX3 hypermethylation is an independent risk factor for progression of BE to HGD or EAC [12] 
Lung MSP NSCLC, surgically treated, n=120 
RUNX3 methylation was more frequent in females than males, non-smokers than smokers, well 
differentiated compared to moderetly or poorly differentiated tumors, ADC than in SCC) and  in 
non-vascularly invasive tumors 
[86] 
 IHC ADC, surgically treated, n=98 
Positive RUNX3 expression frequently seen in ADC with bronchioalveoloar component than those 
without, decreased RUNX3 expression correlated with poor differentiation 
[89] 
Breast MSP and IHC 
Breast cancer (histology unknown), surgically 
treated, n=37 
RUNX3 methylation correlated significantly with positive ER expression  [27] 
 MSP and IHC IDC, surgically treated, n=23 RUNX3 methylation correlated with both positive ER and PR expression [30] 
Urinary 
bladder 
qRT-MSP TCCs, surgically treated, n=304 
RUNX3 methylation increases with age in smokers. TCCs from smokers are older than those from 
non-smokers 
[82] 
 MSP TCCs, surgically treated, n=57 RUNX3 methylation was associated with tumors with invasion of muscularis propria [27] 
EAC, esophageal adenocarcinoma; ESCC, esophageal squamous cell carcinoma; SCC, squamous cell carcinoma of lung; BE, Barrett's esophagus; MSI-H, microsatellite instability-high; MSS, microsatellite 
stable; mtMSI, mitochondrial microsatellite instability; mtMSS, mitochondrial MSS; nMSI, nuclear microsatellite instability; GC, gastric cancer; ADC, adenocarcinoma; NSCLC, non-small cell lung cancer; IDC, 
invasive ductal carcinoma; HCC, hepatocellular carcinoma; TCC, transitional cell carcinoma; BDCa, bile duct carcinoma; GBCa, gall bladder carcinoma; AMPCa, ampullary carcinoma; MSP, methylation-
specific PCR; qRT-MSP, quantitative real time MSP; CRC, colorectal cancer; COBRA, combined bisulfite restriction analysis; HGD, high-grade dysplasia; ER, estrogen; PR, progesterone 
Table 3 Prognostic association of RUNX3 
Tumor type Assay Patient cohort Association Reference 
Gastric IHC GC, surgically treated, n=86 
Positve RUNX3 expression predicted longer overall survival, while loss or weak expression was associated 
with poor survival 
 [104] 
 IHC GC, surgically treated, n=95 Loss of RUNX3 expression correlated with lymph node metastasis and poor survival [116] 
 IHC GC, surgically treated, n=97 Loss of RUNX3 expression was associated with poor clinical outcome [101] 
Colonic MethyLight MSS metastatic CRC, n=30 




Sporadic CRC, surgically treated,  (Stages I-IV), 
n=849 
Loss of nuclear RUNX3 expression and increasing cytoplasmic accumulation of RUNX3 (inactive RUNX3) 




RT-PCR HCC, surgically treated, n=41 
Decreased RUNX3 expression  was associated with advanced stage of disease and loss of 
heterozygosity-detected cases 
[72] 
 MSP ADC of pancreas surgically treated, n=32 RUNX3 hypermethylation was associated with worse prognosis [79] 
Esophageal RT-PCR/ISH ESCC, surgically treated, n=61 
Loss of RUNX3 expression was correlated to worse survival. In early (T1/T2) tumors,  prevalence of lymph 
vessel invasion and positive lymph nodes were significantly higher in RUNX3-negative tumors 
[68] 
 IHC/MSP 
ESCC, n=62, preradiotherapy (endoscopic biopsy) 
and post-radiotherapy (resection) samples 
Nuclear RUNX3 expression was associated with better radiosensitivity and prognosis while 
cytoplasmic/negative RUNX3 was correlated to radioresistance and poor prognosis 
[69] 
 IHC ESCC,surgically treated, n=66 
3yr survival rate was lower in patients with decreased RUNX3 expression than those with positive 
expression 
[70] 
Lung MSP NSCLC, surgically treated, n=101 RUNX3 methylation was correlated to shorter survival for all stages as well as for ADC [90] 
 MSP NSCLC, surgically treated, n=25 RUNX3 methylation was more prevalent in advanced lung cancer (stage III) [87] 
 IHC ADC, surgically treated, n=98 







TCCs, surgically treated transurethral biopsies, 
n=118 
RUNX3 methylation was correlated to muscle invasion, tumor progression and overall and cancer-specific 
survival 
[81] 
 MSP TCCs, surgically treated, n=124 
RUNX3 methylation was associated with 100 fold risk of bladder cancer, tumor stage and recurrence. 
RUNX3 methylation was more frequent in invasive compared to superficial tumors 
[80] 
Prostate  MSP PCA, surgically treated, n=50 RUNX3 methylation was associated with poorer disease-free prognosis [27] 
 MSP PCA, surgically treated, n=37 RUNX3 methylation was associated with cancers with high serum PSA and high Gleason score [21] 
Breast  IHC IDC, surgically treated, n=88 
Positive RUNX3 expression was correlated to clinical stage, lymphnode metastasis and ER and PR 







Oral SCC (n=85) 
ACC of salivary gland (n=73) 
HNSCC ( n=52) 
Low RUNX3 expression was correlated to poor survival in oral SCCs 
Loss of RUNX3 was correlated to poor survival and distant metastasis in ACCs of salivary glands 
Positive RUNX3 expression correlated with invasive and metastatic tumors 
[95]     
[96]     
[35] 
GC, gastric cancer; CRC, colorectal cancer; ESCC, esophageal squamous cell carcinoma; TCC, transitional cell carcinoma;AC, adenocarcinoma; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; 
mtMSI, mitochondrial microsatellite instability; MSS, microsatellite stable; CRC, colorectal cancer; NSCLC, non small cell lung cancer; ADC, adenocarcinoma; PCA, prostate cancer; PSA, prostate specific 
antigen SCC, squamous cell carcinoma; ACC, adenoid cystic carcinoma; IDC, invasive ductal carcinoma; CIMP, CpG island methylator phenptype; RT-PCR, real time polymerase chain reaction; MSP, 
methylation specific PCR; IHC, immunohistochemistry; ISH, in situ hybridization;ER, estrogen receptor; PR, progesterone receptor 
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